[Effects of different treatments on plasma t-PA and PAI activity in AMI].
In the present study, we determined and compared plasma t-PA and PAI activity in 58 AMI patients receiving thrombolytic therapy with UK and snake venom antithrombus enzyme (SVATE) or routine therapy during 3 weeks, and also in 24 healthy subjects. Plasma t-PA activity was decreased and plasma PAI activity increased significantly in patients with AMI as compared to normal controls. UK induced an immediate and transient increase in t-PA and a decrease in PAI activity (P < 0.001, respectively), followed by an increase in PAI activity until 21 days. Treatment with SVATE caused an increase in t-PA activity which remained above the normal level at 21 days, and a decrease in PAI activity which reached the normal level by 7 days. Routine therapy resulted in only slow changes in t-PA and PAI activity. These results indicate that UK and SVATE may be effective in the treatment of AMI.
Zhu
G
G
Institute of Basic Medical Sciences, CAMS, Beijing.
D000328:Adult; D000368:Aged; D000721:Ancrod / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000097:blood / Q000188:drug therapy*; D015849:Plasminogen Inactivators / Q000097:blood*; D015912:Thrombolytic Therapy; D010959:Tissue Plasminogen Activator / Q000097:blood*; D014568:Urokinase-Type Plasminogen Activator / Q000627:therapeutic use*
D015849:Plasminogen Inactivators; D000721:Ancrod; D010959:Tissue Plasminogen Activator; D014568:Urokinase-Type Plasminogen Activator